Net sales of DARZALEX ® in the first quarter of 2026 totaled USD 3,964 million; Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J ...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated ...
QUVIVIQ® in Taiwan, a market with approximately 4–5 million patients, with launch planned during 2026; QUVIVIQ® i ...
Clinical Risk, Regulatory Reality, and the Path to Scale Panel date and time: Monday, April 27, 11:00 AM ET Please contact your Needham representative for access to the panel presentation Live ...
The poster presentation entitled “MST‑0312: Targeted LTBR Agonist Designed to Induce Tertiary Lymphoid Structures and High Endothelial Venules for the Treatment of Solid Tumors,” will detail ...
Medical oncologist (ex AstraZeneca, MorphoSys, Autolus Therapeutics) joins to advance Asgard’s lead asset AT-108 into Phase 1 clinical development AT-108 is a transformative immunotherapy that ...
Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026 Total product sales rose by 51% to USD 43.4 million (Q1 2025: USD 28.8 million) Direct MagnetOs™ ...
Bagsværd, Denmark, 14 April 2026 – Novo Nordisk today announced a strategic partnership with OpenAI that will place Novo Nordisk at the forefront of AI transformation in healthcare and help the ...
Regulatory submission filed to initiate a Phase 2a trial of its drug candidate, PTI5803 in patients with focal cortical dysplasia (FCD), a rare and severe form of epilepsy PannTheraPi secures European ...
Weight management concerns should be discussed with a qualified healthcare professional before starting any prescription program. Vital Step provides publicly available information outlining how its ...
Bowsprit Partners is a UK-based, FCA-authorised advisory firm and recognised Listing Sponsor on Euronext, with extensive experience supporting publicly listed companies across European growth markets.
Effective April 15, 2026, the independent members of the Board of Directors of ImmuCell will be Dr. David Tomsche DVM (Chair), Ms. Gloria Basse, Dr. Anthony DiMarco Ph.D., Dr. Gilles Guillemette DVM, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results